Patents Examined by Nizal S. Chandrakumar
  • Use of Favipiravir in treatment of coronavirus infection
    Patent number: 11318135
    Abstract: The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: May 3, 2022
    Assignee: Academy of Military Medical Sciences
    Inventors: Wu Zhong, Ruiyuan Cao, Cheng Cao, Ting Gao, Gengfu Xiao, Zhihong Hu, Manli Wang, Leike Zhang, Song Li
  • Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9
    Patent number: 11319318
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R9, X1 and X2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, e.g. cancer, pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: May 3, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Laetitia Martin, Steffen Steurer, Xiao-Ling Cockcroft
  • Treatment of congenital adrenal hyperplasia
    Patent number: 11311544
    Abstract: CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: April 26, 2022
    Assignee: Neurocrine Biosciences, Inc.
    Inventor: Dimitri E. Grigoriadis
  • Process for preparation of 2-(6-nitropyridin-3-yl)-9H-dipyrido[2,3-b;3?,4?-d]pyrrole
    Patent number: 11306093
    Abstract: A process for preparing the compound of formula I comprising: a) coupling a compound of formula 2 wherein a leaving group O—SO2—R is selected from the triflate group, the tosylate group, the mesylate group, the besylate group, the nosylate group or the brosylate group, with a suitable boronic acid, a trifluoroborate or a boronic acid ester under argon condition and in the presence of a catalyst and a base in a suitable solvent and then isolating the product as an acid addition salt to afford the compound of formula Ia and b) converting the acid addition salt of formula Ia wherein the acid HX comprises suitable organic or inorganic acids into the compound of formula I by treatment with at least a stoichiometric equivalent of a suitable base.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: April 19, 2022
    Assignee: Hoffmann-La Roche, Inc.
    Inventors: Bjoern Bartels, Philipp Cueni, Matthias Koerner, Dieter Muri
  • Materials for organic electroluminescent devices
    Patent number: 11296281
    Abstract: The present invention relates to dibenzofuran and dibenzothiophene derivatives, especially for use as triplet matrix materials in organic electroluminescent devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: April 5, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Amir Parham, Thomas Eberle, Anja Jatsch, Tobias Grossmann, Jonas Valentin Kroeber
  • Synthetic progestogens and pharmaceutical compositions comprising the same
    Patent number: 11291633
    Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: April 5, 2022
    Assignee: LABORATORIOS LEON FARMA SA
    Inventors: Philippe Perrin, Jose Luis Velada, Dominique Drouin
  • Synthetic progestogens and pharmaceutical compositions comprising the same
    Patent number: 11291632
    Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: April 5, 2022
    Assignee: LABORATORIOS LEON FARMA SA
    Inventors: Philippe Perrin, Jose Luis Velada, Dominique Drouin
  • Spot-on active substance formulation
    Patent number: 11278022
    Abstract: The invention relates to an improved composition for the control of parasites on animals, comprising comparably high amounts of active substances from the group of agonists of the nicotinergic acetylcholine receptors of insects (neonicotinoids) and from pyrethroids in a new and improved formulation comprising carvacrol as a solvent, and optionally additionally further active and/or auxiliary substances. In particular, the invention relates to the use of such compositions for the control of ectoparasites such as, in particular, fleas, ticks and sand flies in pets such as, in particular, in dogs and ferrets.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: March 22, 2022
    Assignee: Evergreen Animal Health, LLC
    Inventors: Olaf Hansen, Rudy Thoma
  • Alvocidib prodrugs and their use as protein kinase inhibitors
    Patent number: 11279694
    Abstract: Compounds having the following structure (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined herein, and wherein at least one of R1, R2 and R3 is not H, are provided. Pharmaceutical compositions comprising the compounds and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: March 22, 2022
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Yusuke Sawayama, Wataru Hirose, Hitoshi Ban
  • Compounds and their methods of use
    Patent number: 11278535
    Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.
    Type: Grant
    Filed: August 15, 2018
    Date of Patent: March 22, 2022
    Assignee: PRAXIS PRECISION MEDICINES, INC.
    Inventors: Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
  • Azole compounds as ubiquitin-specific protease USP7 inhibitors
    Patent number: 11273154
    Abstract: Method and compounds for treating cancer by, for example, modulating immune system activity, are provided.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 15, 2022
    Assignee: PROGENRA, INC.
    Inventors: Hui Wang, Jian Wu, Suresh Kumar Kizhakkethil-George, Feng Wang, Joseph Weinstock
  • Substituted imidazoquinolines
    Patent number: 11267813
    Abstract: The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: March 8, 2022
    Inventor: Christophe Henry
  • Methods for producing ferric maltol compositions from ligand modified and ligand coated ferric hydroxides
    Patent number: 11267836
    Abstract: Methods for producing ferric maltol compositions, such as ferric trimaltol, are described in which maltolis reacted with a ligand modified ferric hydroxide and/or a ligand coated ferric hydroxide.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: March 8, 2022
    Assignee: SHIELD TX (UK) LIMITED
    Inventors: Jonathan Joseph Powell, Nuno Jorge Rodrigues Faria
  • Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
    Patent number: 11266663
    Abstract: Described herein are neurosteroids and analogues thereof and derivatives thereof, including, but not limited to, allopregnanolone, allopregnanolone analogues, and derivatives thereof that can be used for treatment of a neuropsychiatric disorder and/or symptom thereof. Also described herein are pharmaceutical formulations containing an effective amount of a neurosteroids and analogues thereof and derivatives thereof, where the effective amount can be effective for treating a neuropsychiatric disorder and/or symptom thereof. Also described herein are methods of treating a neuropsychiatric disorder and/or a symptom thereof in a subject in need thereof.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: March 8, 2022
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Graziano Pinna, Andrea Locci
  • Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy
    Patent number: 11261157
    Abstract: The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3-yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5? adenosine monophosphate-activated protein kinase (AMPK).
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: March 1, 2022
    Assignee: NovaTarg, Inc.
    Inventors: Kenneth Batchelor, Jeffery E. Cobb, Kristjan S. Gudmundsson, Brad R. Henke, Francis X. Tavares
  • Benzimidazole-carboxamide compounds as 5-HTreceptor agonists
    Patent number: 11254655
    Abstract: The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: February 22, 2022
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventor: Robert Murray McKinnell
  • Inhibiting CREB binding protein (CBP)
    Patent number: 11254674
    Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: February 22, 2022
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Shawn E. R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela West, Jennifer R. Downing, Anna Ericsson
  • Muscarinic agonists
    Patent number: 11254656
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R1, R2?, R2?, R3 and R4 are as defined herein.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: February 22, 2022
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Julie Elaine Cansfield, Mark Pickworth, Benjamin Gerald Tehan, Barry John Teobald
  • Vaginal inserted estradiol pharmaceutical compositions and methods
    Patent number: 11246875
    Abstract: Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: February 15, 2022
    Assignee: TherapeuticsMD, Inc.
    Inventors: Brian A. Bernick, Julia M. Amadio, Sebastian Mirkin
  • Ketone bodies to protect tissues from damage by ionizing radiation
    Patent number: 11234953
    Abstract: Described herein is the surprising discovery that ketone bodies protect cell and tissues from ionizing radiation. Based on this finding, methods of protecting animal tissue and cells from damage caused by radiation exposure are disclosed which include, contacting the tissue with a therapeutically effective amount of an agent including at least one ketone ester, thereby protecting the tissue from radiation damage. Ketone esters can be used to minimize, reduce and/or prevent tissue damage following intentional and accidental radiation exposure, as well as increasing the therapeutic efficacy of radiation therapies by protecting non-target tissue from incidental radiation damage.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: February 1, 2022
    Assignees: TDELTAS LIMITED, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Richard Lewis Veech, Kieran Clarke